ASP Isotopes (NASDAQ:ASPI) CEO Paul Elliot Mann Sells 83,758 Shares

ASP Isotopes Inc. (NASDAQ:ASPI) CEO Paul Mann sold 83,758 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $3.91, for a total value of $327,493.78. Following the completion of the transaction, the chief executive officer owned 9,496,087 shares in the company, valued at approximately $37,129,700.17. The trade was a 0.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Paul Elliot Mann also recently made the following trade(s):

• On Friday, September 4th, Paul Mann sold 83,759 shares of ASP Isotopes stock. The stock was sold at an average price of $4.10, for a total transaction of $343,411.90.

ASP Isotopes Stock Performance

Shares of ASPI opened at $4.20 on Friday. The company has a 50-day simple moving average of $4.37 and a two-hundred day simple moving average of $5.20. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.87 and a quick ratio of 3.85. The firm has a market capitalization of $643.90 million, a PE ratio of -3.18 and a beta of 3.59. ASP Isotopes Inc. has a one year low of $3.51 and a one year high of $14.49.

ASP Isotopes (NASDAQ:ASPI) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.11). The business had revenue of $5.12 million for the quarter, compared to the consensus estimate of $4.47 million. ASP Isotopes had a negative return on equity of 64.99% and a negative net margin of 427.98%.

Analyst Ratings Changes

A number of research analysts have issued reports on ASPI shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of ASP Isotopes in a research note on Wednesday, June 24th. Wall Street Zen raised ASP Isotopes from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 22nd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, ASP Isotopes has a consensus rating of “Hold” and a consensus target price of $13.00.

Hedge Funds Weigh In On ASP Isotopes

Several hedge funds and other institutional investors have recently bought and sold shares of ASPI. Quantbot Technologies LP bought a new stake in shares of ASP Isotopes in the third quarter worth approximately $34,000. BNP Paribas Financial Markets raised its stake in ASP Isotopes by 84.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock valued at $41,000 after buying an additional 2,548 shares during the last quarter. State of Wyoming bought a new position in shares of ASP Isotopes during the 1st quarter valued at $29,000. Allworth Financial LP bought a new position in ASP Isotopes in the second quarter valued at about $51,000. Finally, Legal & General Group Plc lifted its holdings in ASP Isotopes by 30.4% in the third quarter. Legal & General Group Plc now owns 8,377 shares of the company’s stock valued at $81,000 after acquiring an additional 1,953 shares during the period. Institutional investors own 16.80% of the company’s stock.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.